In a filing, Seelos Therapeutics Inc revealed its insider Mehra Raj acquired Company’s shares for reported $99999.0 on Dec 01 ’23. In the deal valued at $1.32 per share,75,757 shares were bought. As a result of this transaction, Mehra Raj now holds 185,142 shares worth roughly $72205.38.
Then, Golembiewski Michael Joseph bought 83,000 shares, generating $100,222 in total proceeds. Upon buying the shares at $1.21, the Chief Financial Officer now owns 86,450 shares.
ROTH Capital upgraded its Seelos Therapeutics Inc [SEEL] rating to a Buy from a a Neutral in a research note published on September 27, 2021; the price target was increased to $8 from $2.50. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering SEEL with “an Overweight” recommendation on June 01, 2021. ROTH Capital revised its rating on May 17, 2021. It rated SEEL as “a Neutral” which previously was an “a Buy”.
Price Performance Review of SEEL
On Tuesday, Seelos Therapeutics Inc [NASDAQ:SEEL] saw its stock fall -11.67% to $0.39. Over the last five days, the stock has lost -22.04%. Seelos Therapeutics Inc shares have fallen nearly -72.29% since the year began. Nevertheless, the stocks have fallen -98.35% over the past one year. While a 52-week high of $49.80 was reached on 01/09/24, a 52-week low of $0.37 was recorded on 03/19/24. SMA at 50 days reached $0.7935, while 200 days put it at $12.2863. A total of 0.55 million shares were traded, compared to the trading of 0.29 million shares in the previous session.
Levels Of Support And Resistance For SEEL Stock
The 24-hour chart illustrates a support level at 0.3668, which if violated will result in even more drops to 0.3484. On the upside, there is a resistance level at 0.4217. A further resistance level may holdings at 0.4582. The Relative Strength Index (RSI) on the 14-day chart is 27.90, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0938, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.97%. Stochastics %K at 4.13% indicates the stock is a buying.
The most recent change occurred on March 30, 2021 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
